Alex Zhavoronkov, PhD
Dr. Alex Zhavoronkov is the CEO of Insilico Medicine, a Baltimore-based leader in the next-generation artificial intelligence and blockchain technologies for drug discovery, biomarker development, and aging research, and one of the Longevity Science Foundation’s Visionary Board members.
At Insilico, Alex pioneered generative adversarial networks and reinforcement learning techniques for generating novel molecular structures with the desired properties. He set up the R&D centres in 6 countries, including Korea, Russia, and Taiwan and launched multiple biomarker initiatives, including Young.AI.

Before founding Insilico Medicine, Alex worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI. He also created AgeNet.net, a platform with contests, hackathons and resources for aging biomarker development competitions and led diversity.AI initiative.

Since 2012 he has published over 80 peer-reviewed research papers and books, including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy”. He is also the co-organiser of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at EMBO/Basel Life, one of Europe's most significant industry events in drug discovery.

Dr. Zhavoronkov holds two Bachelor degrees from Queen’s University, a Master’s in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University.
LONGEVITY SCIENCE FOUNDATION —
PUBLIC ACCESS TO PROPRIETARY BIOTECH THROUGH DECENTRALIZED PARTICIPATION

© ALL RIGHTS RESERVED, 2021
Make a Donation
If you are interested please leave your information below and we will contact you
Name, Surname
Your Email
Country of Residence
This website uses cookies to ensure you get the best experience
OK